ivacaftor + lumacaftor + tezacaftor + elexacaftor

A fixed-dose combination of four cystic fibrosis transmembrane conductance regulator (CFTR) modulators—elexacraft, tezacraft, ivaca and lumaca—is not currently approved or marketed. The closest approved triple-combination therapy is **Trikafta** (elexa+teza+iva), which treats cystic fibrosis in patients with at least one F508del mutation or certain other mutations. **Orkambi** (luma+iva) treats patients with two F508del mutations[2][3][5]. The specific quadruple combination you mention does not exist as a marketed product. For completeness: - **Lumaca**: CFTR correctors improve protein folding and trafficking to the cell surface. - **Tezaca**: CFTR correctors also help with protein folding and trafficking. - **Elexa**: Next-generation CFTR correctors that further enhance protein function. - **Iva**: CFTR potentiators increase channel open probability at the cell surface.

Other names

elexacaftor/tezacaftor/ivacaftorlumacaftor/ivacaftor